Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 4Topotecan 3Ifosfamide 3Doxorubicin 3seclidemstat 2pazopanib 2Biopsy 2tebentafusp 1selinexor 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1fludarabine phosphate 1fludarabine 1dostarlimab 1devimistat 1cobimetinib 1cabozantinib 1atezolizumab 1Zoledronic Acid 1X-Rays 1Vemurafenib 1Sunitinib 1Specimen Handling 1Sirolimus 1Simvastatin 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Proton Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Clear Cell × ARQ 197 × Sarcoma × Clear all
NCT00557609 2013-02-08

Phase 2 Study in Patients With MiT Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 2 Completed
47 enrolled
GenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡